Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (27) clinical trials

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian Fallopian Tube Uterine or Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine whether cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) followed by postoperative normothermic intraperitoneal (IP) chemotherapy is feasible and safe to administer, as measured by toxicities occurring during treatment or follow-up. SECONDARY OBJECTIVES: I. To determine quality of life (QoL) and compare the outcomes to a ...

Phase

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD Pembrolizumab or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC Primary Peritoneal or Fallopian Tube Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer

This study is a first-in-human study designed to establish preliminary human safety, tolerability and pharmacokinetic parameters of Prolanta monotherapy in patients with recurrent or persistent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. In addition, biomarkers related to the activity of human prolactin will be examined in tumor samples ...

Phase

A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

This is a single arm, single center, open-label, Phase 1, first time in human study of COTI-2 in patients with recurrent ovarian,fallopian tube,primary peritoneal cancer, endometrial, cervical or head and neck cancer. COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free ...

Phase

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary peritoneal cancer meeting one of the following minimal prior treatment requirement: Platinum resistant: may receive FATE-NK100 as ...

Phase

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

This is an open-label (identity of assigned study drug will be known) study to evaluate the safety, pharmacokinetics (study of what the body does to a drug), pharmacodynamics (study of what a drug does to the body), and anti-tumor activities of STM 434 (an inhibitor of activin A) in patients ...

Phase

Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination ...

Phase

Phase I Study of Cantrixil in Patients With Ovarian Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer.

This study is a progressive design with 2 discrete Parts (Part A: Dose escalation, Part B: Dose expansion. Cycle 1/Part A is a dose-finding assessment (dose escalation) to establish the MTD of Cantrixil when administered as a single dose once a week for 3 weeks. Cycle2/Part A continues with 3 ...

Phase

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

7 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab. This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and ...

Phase

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose (RPTD) of combination lenvatinib mesylate (lenvatinib) and weekly paclitaxel in patients with recurrent endometrial, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. SECONDARY OBJECTIVES: I. To determine the safety and tolerability of combination lenvatinib and weekly paclitaxel in patients with ...

Phase